Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Daratumumab · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Regimens A-A4 | EXPERIMENTAL | FT576 single dose monotherapy in subjects with r/r MM |
| Regimen A1 | EXPERIMENTAL | FT576 multiple dose monotherapy in subjects with r/r MM |
| Regimens B-B4 | EXPERIMENTAL | FT576 single dose in combination with daratumumab in subjects with r/r MM |
| Regimen B1 | EXPERIMENTAL | FT576 multiple dose in combination with daratumumab in subjects with r/r MM |
| Name | Type | Description |
|---|---|---|
| FT576 (Allogenic CAR NK cells with BCMA expression) | DRUG | Experimental Interventional Therapy: FT576 comprises allogeneic natural killer (NK) cells, derived from a clonal, CD38-knockout, human-induced pluripotent stem cell line (iPSC) that expresses anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR), high-affinity, non-cleavable CD16 (hnCD16), and IL-15/IL-15 receptor fusion protein (IL-15RF). |
| Cyclophosphamide | DRUG | Conditioning Agent |
| Fludarabine | DRUG | Conditioning Agent |
| Daratumumab | DRUG | Anti-CD38 Monoclonal Antibody |
| Bendamustine | DRUG | Conditioning Agent |
* Abbreviated inclusion criteria: Diagnosis of r/r MM with measurable disease by at least one of the following: * Serum M-protein ≥1.0 g/dL * Urine M-protein ≥200 mg/24 hours * Involved serum free light chain level ≥10 mg/dL, with an abnormal kappa-lambda ratio if the serum M-protein \<1.0 g/dL an...
Top 20 of 25 competitors
Daratumumab is an investigational small molecule being developed by Fate Therapeutics, Inc. (NASDAQ: FATE) for the treatment of Multiple Myeloma. It is currently in Phase 1 clinical development and is not yet approved by the FDA.
Daratumumab is being studied for the treatment of Multiple Myeloma, a cancer of plasma cells. It is intended for use in adult patients aged 18 years and older. The drug is currently in Phase 1 clinical trials to evaluate its safety and efficacy in this patient population.
Daratumumab is being developed by Fate Therapeutics, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol FATE. The company is conducting clinical trials to evaluate the drug's potential as a treatment for Multiple Myeloma.
Daratumumab is in Phase 1 clinical development. It is an investigational drug and has not yet received FDA approval. The drug is being studied in a completed Phase 1 trial for Multiple Myeloma, with results expected to inform further development.
Daratumumab has been studied in one clinical trial, identified as NCT05182073, titled 'FT576 in Subjects With Multiple Myeloma'. This Phase 1 trial was conducted in the United States and enrolled 31 participants with Multiple Myeloma. The trial has been completed.
Yes, Daratumumab is also known as FT576. The clinical trial NCT05182073, which evaluated the drug in patients with Multiple Myeloma, used the name FT576 in its title. Both names refer to the same investigational drug being developed by Fate Therapeutics.